JP2003533167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003533167A5 JP2003533167A5 JP2000583963A JP2000583963A JP2003533167A5 JP 2003533167 A5 JP2003533167 A5 JP 2003533167A5 JP 2000583963 A JP2000583963 A JP 2000583963A JP 2000583963 A JP2000583963 A JP 2000583963A JP 2003533167 A5 JP2003533167 A5 JP 2003533167A5
- Authority
- JP
- Japan
- Prior art keywords
- desamino
- peptide
- ser
- composition
- hpth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 239000000203 mixture Substances 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000012634 fragment Substances 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 6
- RRBCHMCWWOHRQL-UMXFMPSGSA-N parathyroid hormone (1-34)amide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CN=CN1 RRBCHMCWWOHRQL-UMXFMPSGSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- OXZNHYPGOAWYLT-FISSOZIDSA-N ostabolin Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)OC(=O)CC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1C=NC=N1 OXZNHYPGOAWYLT-FISSOZIDSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108010067557 parathyroid hormone (1-34)amide Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11015298P | 1998-11-25 | 1998-11-25 | |
| US60/110,152 | 1998-11-25 | ||
| PCT/US1999/027656 WO2000031137A1 (en) | 1998-11-25 | 1999-11-23 | Amino-terminal modified parathyroid hormone (pth) analogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003533167A JP2003533167A (ja) | 2003-11-11 |
| JP2003533167A5 true JP2003533167A5 (enExample) | 2007-02-01 |
Family
ID=22331485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000583963A Pending JP2003533167A (ja) | 1998-11-25 | 1999-11-23 | アミノ末端改変副甲状腺ホルモン（ｐｔｈ）アナログ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6537965B1 (enExample) |
| EP (1) | EP1175444B1 (enExample) |
| JP (1) | JP2003533167A (enExample) |
| AT (1) | ATE384743T1 (enExample) |
| AU (1) | AU1918300A (enExample) |
| DE (1) | DE69938064T2 (enExample) |
| WO (1) | WO2000031137A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023594A1 (en) * | 1998-10-22 | 2000-04-27 | The General Hospital Corporation | BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP) |
| JP4486258B2 (ja) * | 1998-11-25 | 2010-06-23 | ザ・ジェネラル・ホスピタル・コーポレイション | ヒト副甲状腺ホルモンの改変、調製および使用 |
| WO2000032771A1 (en) * | 1998-11-30 | 2000-06-08 | The General Hospital Corporation | Pth1r and pth3r receptors, methods and uses thereof |
| WO2000039278A2 (en) * | 1998-12-31 | 2000-07-06 | The General Hospital Corporation | Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| ATE308609T1 (de) | 1998-12-31 | 2005-11-15 | Gen Hospital Corp | Pth rezeptor und testverfahren unter verwendung desselben |
| US7057012B1 (en) * | 1998-12-31 | 2006-06-06 | The General Hospital Corporation | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| WO2001023521A2 (en) * | 1999-09-29 | 2001-04-05 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
| US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| AU2001292905A1 (en) * | 2000-09-19 | 2002-04-02 | Curagen Corporation | Method of identifying osteoregenerative agents using differential gene expression |
| KR100491737B1 (ko) * | 2001-07-20 | 2005-05-27 | 주식회사 한국아이템개발 | 공기 정화 기능의 모기 퇴치기 |
| WO2003009804A2 (en) | 2001-07-23 | 2003-02-06 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
| MXPA04001418A (es) * | 2001-08-17 | 2004-05-27 | Novartis Ag | Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides. |
| EP1513547A4 (en) | 2002-05-23 | 2009-11-04 | Michael F Holick | USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY |
| US7799757B2 (en) * | 2002-06-13 | 2010-09-21 | Michael Chorev | Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents |
| AU2002951372A0 (en) * | 2002-09-13 | 2002-09-26 | St Vincent's Institute Of Medical Research | Parathyroid hormone-like polypeptides |
| US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| WO2004093902A1 (en) * | 2003-03-19 | 2004-11-04 | The General Hospital Corporation | CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS |
| CN1822853A (zh) * | 2003-07-15 | 2006-08-23 | 加拿大国家研究委员会 | 用于治疗特征在于过度增殖皮肤细胞的疾病的人类甲状旁腺激素环状类似物 |
| US7910544B2 (en) * | 2003-07-17 | 2011-03-22 | The General Hospital Corporation | Conformationally constrained parthyroid hormone (PTH) analogs |
| CN100566669C (zh) * | 2004-05-13 | 2009-12-09 | 阿尔扎公司 | 甲状旁腺激素药物的透皮释放装置 |
| JP5007427B2 (ja) * | 2004-05-13 | 2012-08-22 | アルザ コーポレイション | 副甲状腺ホルモン剤の経皮送達のための装置および方法 |
| JP2009545320A (ja) * | 2006-08-04 | 2009-12-24 | ザ ジェネラル ホスピタル コーポレイション | 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体 |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| US20090023655A1 (en) * | 2007-04-02 | 2009-01-22 | Louis Luttrell | Biased Ligands for Receptors Such as the PTH Receptor |
| CN101784281B (zh) | 2007-08-01 | 2014-07-02 | 总医院有限公司 | 确定g蛋白偶联受体激动剂的方法 |
| EP2411038B1 (en) | 2009-03-27 | 2016-12-28 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
| US9492508B2 (en) | 2010-05-13 | 2016-11-15 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
| WO2019178462A1 (en) | 2018-03-16 | 2019-09-19 | The General Hospital Corporation | Parathyroid hormone polypeptide conjugates and methods of their use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5896052A (ja) * | 1981-11-30 | 1983-06-07 | Toyo Jozo Co Ltd | 高活性ｈ−ＰＴＨ（１−３４）アミドの製造法 |
| US4423037A (en) * | 1982-05-13 | 1983-12-27 | The General Hospital Corporation | Inhibitors of peptide hormone action |
| JPS59204159A (ja) * | 1983-04-28 | 1984-11-19 | Toyo Jozo Co Ltd | 〔Ｍｅｔ（Ｏ）↑８’↑１↑８〕ｈＰＴＨ−（１−３４）ペプチド |
| IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| US5527772A (en) | 1987-10-20 | 1996-06-18 | Holick; Michael F. | Regulation of cell proliferation and differentiation using peptides |
| US5605815A (en) * | 1988-03-14 | 1997-02-25 | Yale University | Nucleic acids encoding and expression of parathyroid hormone-like peptide |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| US5589452A (en) * | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| WO2000023594A1 (en) * | 1998-10-22 | 2000-04-27 | The General Hospital Corporation | BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP) |
| JP4486258B2 (ja) * | 1998-11-25 | 2010-06-23 | ザ・ジェネラル・ホスピタル・コーポレイション | ヒト副甲状腺ホルモンの改変、調製および使用 |
| WO2000032771A1 (en) * | 1998-11-30 | 2000-06-08 | The General Hospital Corporation | Pth1r and pth3r receptors, methods and uses thereof |
-
1999
- 1999-11-23 AT AT99962819T patent/ATE384743T1/de not_active IP Right Cessation
- 1999-11-23 DE DE69938064T patent/DE69938064T2/de not_active Expired - Lifetime
- 1999-11-23 JP JP2000583963A patent/JP2003533167A/ja active Pending
- 1999-11-23 EP EP99962819A patent/EP1175444B1/en not_active Expired - Lifetime
- 1999-11-23 US US09/447,800 patent/US6537965B1/en not_active Expired - Fee Related
- 1999-11-23 WO PCT/US1999/027656 patent/WO2000031137A1/en not_active Ceased
- 1999-11-23 AU AU19183/00A patent/AU1918300A/en not_active Abandoned
-
2003
- 2003-02-11 US US10/361,928 patent/US20030144209A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002528060A5 (enExample) | ||
| JP2002530111A5 (enExample) | ||
| JP2507106B2 (ja) | インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド | |
| US7229964B2 (en) | Insulin derivatives | |
| CA2215694A1 (en) | Insulin derivatives | |
| EP1705190A2 (en) | Peptide derivatives | |
| JP2009525052A5 (enExample) | ||
| JP2004531242A5 (enExample) | ||
| CN101970476A (zh) | 具有超延迟时效特征的新型胰岛素衍生物 | |
| JP2006149406A5 (enExample) | ||
| EP0894095A1 (en) | Insulin derivatives and their use | |
| JP2006187292A5 (enExample) | ||
| WO2008056726A1 (en) | Glp-1 derivative and use thereof | |
| JP2009515529A5 (enExample) | ||
| EP0781142A1 (en) | Compositions and methods for delivery of polypeptides | |
| JP2009545320A5 (enExample) | ||
| EP1513545B1 (en) | Methods and means to promote gut absorption | |
| EP1493747B1 (en) | Process for producing modified peptide | |
| JPH083196A (ja) | カルシトニン誘導体及びその用途 | |
| JP2002516662A5 (enExample) | ||
| EP0511003B1 (en) | Superactive GRF analogs | |
| EP0454367B1 (en) | Growth hormone releasing factor analogs | |
| JPH06220090A (ja) | ポリペプチド | |
| CN101157725B (zh) | 人胰岛素类似物的制备方法及用途 | |
| Yu et al. | Synthesis and biological activity of human calcitonin analogs |